工程化免疫球蛋白G的经胎盘递送治疗性蛋白:迈向围产期替代治疗的一步
研究探讨妊娠小鼠给予或内源性存在的蛋白能否经胎盘递送。构建针对人凝血因子VIII不同结构域的单价免疫球蛋白G(FabFc),与 exogenous FVIII 共同注射至妊娠重型血友病A小鼠或经AAV8介导基因治疗表达人FVIII的妊娠小鼠。FabFc使FVIII以FcRn依赖方式经胎盘递送,胎儿FVIII抗原水平达人类正常血浆水平的10%。
要点
- FabFc可介导FVIII经胎盘递送至胎儿,呈FcRn依赖方式。
- 胎儿FVIII抗原水平达人类正常血浆水平的10%。
- 抗原/FabFc复合物稳定性、抗原大小及屏蔽混杂蛋白斑块是优化递送的关键参数。
核心结论
- 结果为实现经宫内递送内源性母体蛋白以替代遗传性缺陷的胎儿蛋白或教育免疫系统、促进日后遇蛋白时主动免疫耐受的新策略铺平道路。
研究设计与样本
- 构建针对人凝血因子VIII不同结构域的单价免疫球蛋白G(FabFc),与 exogenous FVIII 共同注射至妊娠重型血友病A小鼠或经AAV8介导基因治疗表达人FVIII的妊娠小鼠,用酶联免疫吸附试验和免疫组化检测母鼠和/或胎儿中的FabFc与FVIII。
主要发现
- 妊娠小鼠给予FabFc后,FVIII以FcRn依赖方式经胎盘递送。
- 胎儿中达到的FVIII抗原水平为人类正常血浆水平的10%。
- 抗原/FabFc复合物稳定性、抗原大小及屏蔽混杂蛋白斑块被确定为促进最佳抗原递送的关键参数。
关键数值与推荐
- 胎儿FVIII抗原水平为人类正常血浆水平的10%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplacental delivery of maternal immunoglobulin G (IgG) provides humoral protection during the first months of life until the newborn's immune system reaches maturity. The maternofetal interface has been exploited therapeutically to replace missing enzymes in the fetus, as shown in experimental mucopolysaccharidoses, or to shape adaptive immune repertoires during fetal development and induce tolerance to self-antigens or immunogenic therapeutic molecules. OBJECTIVES: To investigate whether proteins that are administered to pregnant mice or endogenously present in their circulation may be delivered through the placenta. METHODS: We engineered monovalent immunoglobulin G (FabFc) specific for different domains of human factor VIII (FVIII), a therapeutically relevant model antigen. FabFc was injected with exogenous FVIII into pregnant severe hemophilia A mice or pregnant mice expressing human FVIII following AAV8-mediated gene therapy. FabFc and FVIII were detected in the pregnant mice and/or fetuses by enzyme-linked immunosorbent assay and immunohistochemistry. RESULTS: Administration of FabFc to pregnant mice allowed the maternofetal delivery of FVIII in a FcRn-dependent manner. FVIII antigen levels achieved in the fetuses represented 10% of normal plasma levels in the human. We identified antigen/FabFc complex stability, antigen size, and shielding of promiscuous protein patches as key parameters to foster optimal antigen delivery. CONCLUSION: Our results pave the way toward the development of novel strategies for the in utero delivery of endogenous maternal proteins to replace genetically deficient fetal proteins or to educate the immune system and favor active immune tolerance upon protein encounter later in life.
引用
- Mimoun A, Bou-Jaoudeh M, Delignat S, et al. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy. J Thromb Haemost. 2023. PMID: 37271431. doi:10.1016/j.jtha.2023.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。